FREE 2-DAY SHIPPING
When you eat, the food stimulates your gut to release the GLP-1 hormone. GLP-1 helps lower blood glucose (blood sugar) by triggering insulin release. Insulin helps blood glucose enter your body’s cells for later energy use.
In some people, the gut doesn't make enough natural GLP-1, or the brain isn't sensitive to it.
Tirzepatide is a synthetic GLP-1 RA (receptor agonist). A drug that works as an agonist activates the same cell receptors as the body’s natural hormones. Semaglutide works in the gut like the body’s natural GLP-1, slowing digestion, curbing hunger, and signaling fullness to the brain.
Results could mark a "new era" in treating obesity with even more therapies on the horizon.
The most effective drug intervention we have seen for weight management.
In studies, a weekly injection caused dramatic amounts of weight loss and improved other heart-related risk factors.
2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
.png)
These highly effective anti-obesity medications are associated with weight losses of more than 10% of overall bodyweight in more than two-thirds of clinical trial participants.
Results could mark a "new era" in treating obesity with even more therapies on the horizon.
The most effective drug intervention we have seen for weight management.
In studies, a weekly injection caused dramatic amounts of weight loss and improved other heart-related risk factors.
2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
These highly effective anti-obesity medications are associated with weight losses of more than 10% of overall bodyweight in more than two-thirds of clinical trial participants.
Results could mark a "new era" in treating obesity with even more therapies on the horizon.
The most effective drug intervention we have seen for weight management.
In studies, a weekly injection caused dramatic amounts of weight loss and improved other heart-related risk factors.
2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.
These highly effective anti-obesity medications are associated with weight losses of more than 10% of overall bodyweight in more than two-thirds of clinical trial participants.
